Goslik joined Brandon Capital in 2018.
Goslik has spent more than 20 years’ in the life sciences industry, with his experience spanning research, commercial, translation and investment roles.
Goslik is passionate about research commercialisation, with demonstrated skills and experience in licensing, negotiation and deal-making. Prior to joining Brandon Capital Partners, Goslik was the GM of Business Development at Queensland’s largest medical research institute, QIMR Berghofer, where he was responsible for managing and growing the Business Development team. In this role he secured two large-scale, multimillion dollar collaborations with pharma, driving significant revenue and importantly ongoing R&D collaborations for the institute. Goslik also worked as VP Business Development at the biopharmaceutical companies, Alchemia Ltd (AU-ASX) and Summit PLC (UK-AIM), where he closed seminal deals on their small molecule drug discovery platform and animal model and screening platforms, respectively.
Goslik has a strong research foundation with a background in marine biology, microbiology, protein chemistry, and molecular biology. After completing his PhD, Gos worked at Oxford University (Oxford Innovation) where he spun out Oxford’s first ever material sciences company, focused on regenerative medicine.
Goslik is currently a director of Kimaritec and Sicario.
Goslik has a Bachelor of Science from James Cook University, a Bachelor of Science (Honours) from The University of Melbourne and a PhD in Molecular and Development Biology from the University of Queensland. Goslik is a Graduate of the Australian Institute of Company Directors (AICD).